Breaking News
Sort by:
Top Post
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]
Newron Reports Topline Results From All Patients in Study Evaluating Evenamide as Add-on Therapy for Treatment-Resistant Schizophrenia
Newron Pharmaceuticals, a biopharmaceutical company focused on the development of novel therapies for patients with […]
Investigational Oral Osteoarthritis Drug APPA May Have a Promising Senotherapeutic Effect with Potential in Other Diseases of Ageing
New data presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, […]
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
Incyte has announced new data from a Phase 2b clinical trial evaluating the safety and […]
Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Disease
Kuria Therapeutics, a pharmaceutical company developing novel ophthalmic and dermal therapeutics, is pleased to announce […]
Mitsubishi Tanabe Pharma America Announces More Than 10,000 People with ALS Treated with RADICAVA ORS® and/or RADICAVA®
Mitsubishi Tanabe Pharma America today announced that more than 10,000 people with amyotrophic lateral sclerosis […]
Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease
UCB, a global biopharmaceutical company, and Aitia, the leader in the application of Causal AI […]
Kurve Therapeutics Announces Development of New Intellectual Property to Target Drug Delivery in the Brain
Today, Kurve Therapeutics announced it has filed for new intellectual property on its nose to […]
Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older
Mirum Pharmaceuticals today announced that the United States Food and Drug Administration (FDA) has approved […]
InDex Pharmaceuticals Announces Positive Results from a Pharmacokinetic (PK) Study with Cobitolimod
InDex Pharmaceuticals has announced positive results from a pharmacokinetic (PK) study with cobitolimod in patients […]
China National Medical Products Administration Accepts Regulatory Submission for Nucala (mepolizumab) in Severe Eosinophilic Asthma
GSK today announced that the China National Medical Products Administration has accepted for review a […]
- Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Read more
- Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) Read more
- BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Read more
- Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution Read more
- GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Read more